A5003029845- S100 Proteins and Annexins
- Immune cells in cancer
- Immune Response and Inflammation
- CAR-T cell therapy research
- Cancer Research and Treatments
- Protease and Inhibitor Mechanisms
- Blood Coagulation and Thrombosis Mechanisms
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Acute Lymphoblastic Leukemia research
- Hematological disorders and diagnostics
- Retinoids in leukemia and cellular processes
- Signaling Pathways in Disease
- Chemokine receptors and signaling
- Seaweed-derived Bioactive Compounds
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cancer Immunotherapy and Biomarkers
- Pharmacological Effects of Natural Compounds
- Ion channel regulation and function
- Sarcoma Diagnosis and Treatment
- RNA modifications and cancer
- Cancer-related gene regulation
- T-cell and Retrovirus Studies
- Epigenetics and DNA Methylation
- Neuroinflammation and Neurodegeneration Mechanisms
The Wistar Institute
2015-2023
AstraZeneca (United Kingdom)
2023
Luxembourg Institute of Health
2020-2021
Université de Strasbourg
2010-2018
Centre National de la Recherche Scientifique
2014-2018
Inserm
2014-2018
Institut de génétique et de biologie moléculaire et cellulaire
2010-2018
Génétique Moléculaire Génomique Microbiologie
2010
We have identified a precursor that differentiates into granulocytes in vitro and vivo yet belongs to the monocytic lineage. termed these cells monocyte-like precursors of (MLPGs). Under steady state conditions, MLPGs were absent spleen barely detectable bone marrow (BM). In contrast, significantly expanded tumor-bearing mice differentiated polymorphonuclear myeloid-derived suppressor (PMN-MDSCs). Selective depletion had no effect on number naive but decreased population PMN-MDSCs by 50%....
By binding to Notch target genes, Ikaros shuts off the expression of these genes in T cells and prevents development cell acute lymphoblastic leukemia.
New strategies are needed to enhance the efficacy of anti–programmed cell death protein antibody (anti–PD-1 Ab) in cancer. Here, we report that inhibiting palmitoyl-protein thioesterase 1 (PPT1), a target chloroquine derivatives like hydroxychloroquine (HCQ), enhances antitumor anti–PD-1 Ab melanoma. The combination resulted tumor growth impairment and improved survival mouse models. Genetic suppression core autophagy genes, but not Ppt1, cancer cells reduced priming cytotoxic capacity...
The role of myeloid cells as regulators tumor progression that significantly impact the efficacy cancer immunotherapies makes them an attractive target for inhibition. Here we explore effect a novel, potent, and selective inhibitor serine/threonine protein kinase casein 2 (CK2) on modulating in microenvironment. Although inhibition CK2 caused only modest dendritic tumor-bearing mice, it substantially reduced amount polymorphonuclear myeloid-derived suppressor tumor-associated macrophages....
Multiple myeloma is characterized by clonal proliferation of plasma cells that accumulate preferentially in the bone marrow (BM). The tumor microenvironment one leading factors promote progression. Neutrophils and monocytes are a major part BM microenvironment, but mechanism their contribution to multiple progression remains unclear. Here, we describe novel which S100A8/S100A9 proteins produced neutrophils expansion megakaryocytes supporting alone was not sufficient drive megakaryopoiesis...
Natural killer (NK) cells are innate effector lymphocytes with strong antitumor effects against hematologic malignancies such as chronic lymphocytic leukemia (CLL). However, NK fail to control CLL progression on the long term. For effective lysis of their targets, use a specific cell-cell interface, known immunological synapse (IS), whose assembly and function critically rely dynamic cytoskeletal changes in cells. Here we explored role cell actin cytoskeleton during attack. We found that can...
Plasmacytoid and conventional dendritic cells (pDCs cDCs) arise from monocyte progenitors (MDPs) common (CDPs) through gene expression changes that remain partially understood. Here we show the Ikaros transcription factor is required for DC development at multiple stages. cooperates with Notch pathway activation to maintain homeostasis of MDPs CDPs. then antagonizes TGFβ function promote pDC differentiation Strikingly, Ikaros-deficient CDPs pDCs express a cDC-like transcriptional signature...
Abstract Alterations in the myeloipoiesis during cancer lead to production of myeloid-derived suppressor cells (MDSC). MDSC are comprised two subsets: monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC). Both subsets contribute immunosuppressive tumor microenvironment. Therefore elimination could potentially improve clinical success immune therapy. Direct targeting progenitors is an attractive possibility. Our laboratory has recently discovered that M-MDSC from bone-marrow can give rise...
<div>Abstract<p>The role of myeloid cells as regulators tumor progression that significantly impact the efficacy cancer immunotherapies makes them an attractive target for inhibition. Here we explore effect a novel, potent, and selective inhibitor serine/threonine protein kinase casein 2 (CK2) on modulating in microenvironment. Although inhibition CK2 caused only modest dendritic tumor-bearing mice, it substantially reduced amount polymorphonuclear myeloid-derived suppressor...
<p>This file contains Table with the description of antibodies used in study and listing sequence primers study. Supplemental Figure 1 shows antitumor effect CK2 inhibitor, 2 - inhibitors on tumor cells vitro, 3 suppressive activity MDSC inhibitor treated mice, 4 Notch signaling related genes.</p>
<div>Abstract<p>The role of myeloid cells as regulators tumor progression that significantly impact the efficacy cancer immunotherapies makes them an attractive target for inhibition. Here we explore effect a novel, potent, and selective inhibitor serine/threonine protein kinase casein 2 (CK2) on modulating in microenvironment. Although inhibition CK2 caused only modest dendritic tumor-bearing mice, it substantially reduced amount polymorphonuclear myeloid-derived suppressor...
<p>This file contains Table with the description of antibodies used in study and listing sequence primers study. Supplemental Figure 1 shows antitumor effect CK2 inhibitor, 2 - inhibitors on tumor cells vitro, 3 suppressive activity MDSC inhibitor treated mice, 4 Notch signaling related genes.</p>
<p>Effect of TQ in S100A9KO MM-bearing mice.</p>
<p>Effect of TPO and S100A9 on in vitro MK differentiation.</p>
<p>Effect of S100A9 protein on mouse MKs.</p>
<p>BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.</p>
<p>Mechanism of S100A9 effect on MK differentiation.</p>
<p>Effect of TQ on MM cells.</p>